Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody

Cancer Research

Volumn 58, Issue 18, 1998, Pages 4146-4154

  Melani, Cecilia ^a   Figini, Mariangela ^a   Nicosia, Daniela ^a   Luison, Elena ^a   Ramakrishna, Venkatesh ^a,d   Casorati, Giulia ^b   Parmiani, Giorgio ^a   Eshhar, Zelig ^c   Canevari, Silvana ^a   Colombo, Mario P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b HSRaffaele   (Italy)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d Argonex Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID ANTAGONIST; HYBRID PROTEIN; INTERLEUKIN 2; IODINE 125; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; GENETIC TRANSDUCTION; GYNECOLOGIC CANCER; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; CARRIER PROTEINS; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOTHERAPY, ADOPTIVE; IMMUNOTOXINS; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; OVARIAN NEOPLASMS; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS;

EID: 0032530237     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbeck, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., and Frost, P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60: 397-403, 1990.
2. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., and Gilboa, E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med., 172: 1217-1224, 1990.
3. Maass, G., Schmidt, W., Berger, M, Schilcher, F., Koszik, F., Schneeberger, A., Stingl, G., Birnstiel, M. L., and Schweighoffer, T. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA, 92: 5540-5544, 1995.
4. Reisfeld, R. A., Becker, J. C., and Gillies, S. D. Immunocytokines: a new approach to immunotherapy of melanoma. Melanoma Res., 7 (Suppl. 2): S99-S1006, 1997.
5. Fell, H. P., Gayle, M. A., Grosmaire, L., and Ledbetter, J. A. Genetic construction and characterization of a fusion protein consisting of chimeric F(ab′) with specificity for carcinomas and human IL-2. J. Immunol., 146: 2446-2452, 1991.
6. Xiang, J., Liu, E., Moyana, T., and Qi, Y. Single-chain antibody variable regiontargeted interleukin-2 stimulates T cell killing of human colorectal carcinoma cells. Immunol. Cell Biol., 72: 275-285, 1994.
7. Xiang, R., Lode, H. N., Dolman, C. S., Dreier, T., Varki, N. M., Qian, X., Lo, K., Lan, Y., Super, M., Gillies, S. D., and Reisfeld, R. A. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res., 57: 4948-4955, 1997.
8. Lode, H. N., Xiang, R., Dreier, T., Varki, N. M., Gillies, S. D., and Reisfeld, R. A. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood, 91: 1706-1715, 1998.
9. Taylor, A. E., Wiltshaw, E., Gore, M. E., Fryatt, I., and Fisher, C. Long-term follow-up of the first randomized study of cysplatin versus carboplatin for advanced epithelial ovarian cancer. J. Clin. Oncol., 12: 2066-2070, 1994.
10. Kuiper, M., Peakman, M., and Farzaneh, F. Ovarian tumor antigens as potential targets for immune gene therapy. Gene Ther., 2: 7-15, 1995.
11. Ramakrishna, V., Negri, D., Brusic, V., Fontanelli, R., Canevari, S., Bolis, G., Castell, C., and Parmiani, G. Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells. Int. J. Cancer, 73: 143-150, 1997.
12. Miotti, S., Canevari, S., Ménard, S., Mezzanzanica, D., Porro, G., Pupa, S. M., Regazzoni, M., Tagliabue, E., and Colnaghi, M. I. Characterization of human ovarian carcinoma associated antigens defined by novel monoclonal antibodies with tumor restricted specificity. Int. J. Cancer, 39: 297-303, 1987.
13. Epenetos, A. A., Munro, A. J., Stewart, S., Rampling, R., Lambert, H. E., McKenzie, C. G., Soutter, P., Rahemtulla, A., Hooker, G., Sivolapenko, G. B., Snook, D., Courtenay-Luck, N., Dhokia, B., Krausz, T., Taylor-Papadimitriou, J., Durbin, H., and Bodmer, W. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabelled monoclonal antibodies. J. Clin. Oncol., 5: 1890-1899, 1987.
14. 131I-MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur. J. Cancer, 31A: 686-690, 1995.
15. Rath, U., Kaufmann, M., Schmid, H., Hofmann, J., Wiedemann, B., Kist, A., Kempeni, J., Schlick, E., Bastert, G., Kommerell, B., and Mannel, D. Effect of intraperitoneal recombinant human tumor necrosis factor a on malignant ascites. Eur. J. Cancer, 27: 121-125, 1991.
16. Steis, R. G., Urba, W. J., Van der Molen, L. A., Bookman, M. A., Smith, J. W., Clark, J. W., Miller, L. R., Crum, E. D., Beckner, S. K., McKnight, J. E., Ozols, R. F., Stevenson, H. C., Young, R. C., and Longo, D. L. Intraperiloneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J. Clin. Oncol., 8: 1618-1629, 1990.
17. Freedman, R. S., Edwards, C. L., Kavanagh, J. J., Kudelka, A. P., Katz, R. L., Carrasco, C. H., Atkinson, E. N., Scott, W., Tomasovich, B., Templin, S., and Platsoucas, C. D. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J. Immunother., 16: 198-210, 1994.
18. Canevari, S., Stoter, G., Arienti, F., Bolis, G., Colnaghi, M. I., Di Re, E. M., Eggermont, A. M. M., Goey, S. H., Gratama, J. W., Lamers, C. H. J., Nooy, M. A., Parmiani, G., Raspagliesi, F., Ravagnani, F., Scarfone, G., Trimbos, J. B., Warnaar, S. O., and Bolhuis, R. L. H. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst., 87: 1463-1469, 1995.
19. Freedman, R. S., Gibbons, J. A., Giedlin, M., Kudelka, A. P., Kavanagh, J. J., Edwards, C. L., Carrasco, C. H., Nash, M. A., and Platsoucas, C. D. Immunopharmacology and cytokine produclion of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma. J. Immunother., 19: 443-451, 1997.
20. Casalini, P., Mezzanzanica, D., Canevari, S., Della Torr, G., Miotti, S., Colnaghi, M. I., and Matzku, S. Use of a combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen. Analysis of cell binding and iternalization. Int. J. Cancer, 48: 284-290, 1991.
21. Melani, C., Chiodoni, C., Arienti, F., Maccalli, C., Sulé-Suso, J., Anichini, A., Colombo, M. P., and Parmiani, G. Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells. Nat. Immun., 13: 76-84, 1994.
22. Clackson, T., Hoogenboom, H. R., Griffith, A. D., and Winter, G. Making antibody fragments using phage display libraries. Nature (Lond.), 352: 624-628, 1991.
23. Figini, M., Obici, L., Mezzanzanica, D., Griffith, A., Colnaghi, M. I., Winter, G., and Canevari, S. Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res., 58: 991-996, 1998.
24. Oi, V. T., Morrison, S. L., Herzenberg, L. A., and Berg, P. Immunoglobulin expression in transformed lymphoid cells. Proc. Natl. Acad. Sci. USA, 80: 825-829, 1983.
25. Traunecker, A., Schneider, J., Kiefer, H., and Karjalainen, K. Highly efficient neutralizalion of HIV recombinant CD4-immunoglobulin molecules. Nature (Lond.), 339: 68-70, 1989.
26. Coney, L. R., Mezzanzanica, D., Sanborn, D., Casalini, P., Colnaghi, M. L, and Zurawsky, V. R., Jr. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res., 54: 2448-2455, 1994.
27. Bottero, F., Tomassetti, A., Canevari, S., Miotti, S., Ménard, S., and Colnaghi, M. I. Gene transfection and expression of the ovarian carcinoma marker folate-binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res., 53: 5791-5796, 1993.
28. Bénard, J., De Silva, J., De Blois, M. C., Boyer. P., Duvilland, P., Chiric, E., and Riou, G. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res., 45: 4970-4979, 1985.
29. Marchalonis, J. J. An enzymatic method for the trace iodination of immunoglobulin and other proteins. Biochem. J., 113: 299-305, 1969.
30. Gadina, M., Canevari, S., Ripamonti, M., Mariani, M., and Colnaghi, M. I. Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MOv18. Nucl. Med. Biol., 18: 403-408, 1991.
31. Hock, H., Dorsch, M., Kunzendorf, U., Qin, Z., Diamanstein, T., and Blankenstein, T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor, or Interferon γ. Proc. Natl. Acad. Sci. USA, 90: 2774-2778, 1993.
32. Boleti, E., Deonarain, M. P., Spooner, R. A., Smith, A. J., Epenetos, A. A., and George, A. J. T. Construction, expression and characterization of a single chain anti-tumour antibody (scFv)-IL-2 fusion protein. Ann. Oncol., 6: 945-947, 1995.
33. Yokota, T., Milenic, D. E., Whitlow, M., and Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res., 52: 3402-3408, 1992.
34. Savage, P., So, A., Spooner, R. A., and Epenetos, A. A. A recombinant single chain antibody interleukin-2 fusion protein. Br. J. Cancer, 67: 304-310, 1993.
35. Dorai, H., McCartney, J. E., Hudziak, R. M., Tai, M. S., Laminet, A. A., Houston, L. L., Huston, J. S., and Oppermann, H. Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusion with interleukin-2 and other effector domains. Bio-Technology, 12: 890-897, 1994.
36. Gillies, S. D., Reilly, E. B., Lo, K. M., and Reisfeld, R. A. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA, 89: 1428-1432, 1992.
37. Gillies, S. D., Young, D., Lo. K. M., and Roberts, S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Biocon. Chem., 4: 230-235, 1993.
38. Becker, J. C., Varki, N., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. USA, 93: 7826-7831, 1996.
39. Becker, J. C., Pancook, J. D., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med., 183: 2361-2366, 1996.
40. Becker, J. C., Varki, N., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J. Clin. Investig., 98: 2801-2804, 1996.
41. Rosenberg, S.A., Lotze, M. T., Yang, J. C., Aebersold, P. M., Linehan, W. M., Seipp, C., and White, D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg., 210: 474-485, 1989.
42. Parmiani, G. An explanation of the variable clinical response to interleukin 2 and LAK cells. Immunol. Today, 11: 113-115, 1990.
43. Parmiani, G., Colombo, M. P., Melani, C., and Arienti, F. Cytokine gene transduction in the immunotherapy of cancer. Adv. Pharmacol., 40: 259-307, 1997.
44. Shawler, D. L., Fakhrai, H., Van Beveren, C., Mercola, D., Gold, D. P., Bartholomew, R. M., Royston, I., and Sobol, R. E. Gene therapy approaches to enhance antitumor immunity. Adv. Pharmacol., 40: 309-337, 1997.